Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 5 November 2026.
Announcements
6,266
Total raised
£165B
disclosed amounts
This month
£202M
raised so far
M Ventures led the Series B round to support the company ahead of its commercial launch.
"The power of single-cell analysis to uncover the complexities of biology has become increasingly evident, but much of the work still focuses on the transcriptome as the primary readout."
The pre-seed round was led by Target Global with backing from angel investors and creative partners.
"We believe everyone has the ability to take control of their money and build a buffer against the world, so long as they’re given the right conditions, tools and support to do so. We created Communion for people to fix their relationship with money and live life with more autonomy and less fear."
The pre_seed round was led by Dasein Capital with backing from Spatial Capital and Look AI Ventures to support product development.
"Electric Sheep’s cutting-edge cloud and AI platform is poised to revolutionise several core VFX workflows. They’re taking a smart and pragmatic approach to accelerate some of the most tedious post-production tasks."
Playground Global led the Series A round to support the firm in achieving practical quantum advantage.
"For all the advances that have been made in quantum hardware, and for all quantum computing’s promise, such progress could end up being for nothing if we can’t build the applications needed to make the technology truly useful. With our record-breaking algorithms and groundbreaking techniques, we are pushing the boundaries of what is possible in this space. With support from such a renowned deep-tech visionary as Playground, we think practical quantum advantage is achievable in years, not decades."
The funding will increase clinical capacity and support the delivery of Phase I trials for novel medicines.
"BDD is an excellent example of an ambitious and innovative Scottish life science company with global reach. Its patented timed-release technology, alongside world-class clinical trial services offering, created a compelling proposition for the pharma industry. Building on a successful 18 months after the challenges of the pandemic, the company is well poised to pursue its growth strategy. We’re excited by what the future holds for BDD and looking forward to supporting Carol and the team."
